Live
CellMicrobiome-produced nicotinic acid controls colon regional identity and injury susceptibilityCellPapuan admixture predated the settlement of PalauFierceBiotechCNS Pharma wipes glioblastoma pipeline clean in strategic pivot to fresh neurology, oncology targetsFierceBiotechBD taps Sinteco for European pharmacy robotics partnershipFierceBiotechDespite delays, NIH grants generated a 250% return on $36.6B investment in 2025: reportBioPharma DiveFDA clears repurposed GSK drug for ultra-rare brain disease instead of autismLonza NewsLonza Group Ag (OTCMKTS:LZAGY) Short Interest Update - MarketBeatBioPharma DiveLilly unveils $3 billion production expansion in ChinaEndpoints NewsLilly plots GLP-1 pill production boost in China, $500M pledge to South KoreaLonza NewsLonza Expands Agreement to Manufacture Gene Therapy for Transfusion-Dependent Beta-Thalassemia - GEN - Genetic Engineering and Biotechnology NewsEndpoints NewsUCB says Bimzelx tops Skyrizi in trial; Xenon, Dianthus set share salesIlluminaIllumina partnership aims to speed rare disease diagnosis in Florida - AADC News
Cell Mar 11, 2026

Microbiome-produced nicotinic acid controls colon regional identity and injury susceptibility

Microbiome-produced nicotinic acid controls colon regional identity and injury susceptibility

Original
Body unavailable. Use the original source.

Directory

59 All